H
Harvey Dosik
Researcher at New York Methodist Hospital
Publications - 115
Citations - 5517
Harvey Dosik is an academic researcher from New York Methodist Hospital. The author has contributed to research in topics: Leukemia & Population. The author has an hindex of 24, co-authored 115 publications receiving 5323 citations. Previous affiliations of Harvey Dosik include SUNY Downstate Medical Center & Jewish Hospital.
Papers
More filters
Journal ArticleDOI
In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.
Donald J. Giard,Stuart A. Aaronson,George J. Todaro,Paul Arnstein,John H. Kersey,Harvey Dosik,Wade P. Parks +6 more
Journal ArticleDOI
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study
Jerome W. Yates,Oliver Glidewell,Peter H. Wiernik,Cooper,David M. Steinberg,Harvey Dosik,Ronald Levy,C Hoagland,Patrick H. Henry,Arlan J. Gottlieb,Cornelius J. Cornell,Jeffrey L. Berenberg,JL Hutchison,P Raich,Nis I. Nissen,R R Ellison,R Frelick,GW James,Geoffrey Falkson,Richard T. Silver,Farid Haurani,Mark R. Green,Edward S. Henderson,Louis A. Leone,James F. Holland +24 more
TL;DR: The duration of complete remission, with cyclic courses of maintenance therapy, was independent of the patient's age, the dose, or choice of anthracycline used in induction, and of whether the maintenance courses were given every 4 wk or every 8 wk.
Journal ArticleDOI
Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease
Wendell F. Rosse,Dianne Gallagher,Thomas R. Kinney,Oswaldo Castro,Harvey Dosik,John Moohr,Winfred C. Wang,Paul S. Levy +7 more
TL;DR: Patients with sickle cell disease who had been transfused were more frequently alloimmunized than men; this was largely due to the fact that women received more transfusions than men, but in the age group 16 to 20 years the increase may have been due in part to alloIMmunization owing to pregnancy.
Journal ArticleDOI
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up
Martin H. Steinberg,William F. McCarthy,Oswaldo Castro,Samir K. Ballas,F. Danny Armstrong,Wally R. Smith,Kenneth I. Ataga,Paul Swerdlow,Abdullah Kutlar,Laura DeCastro,Myron A. Waclawiw,Eugene P. Orringer,Susan Jones,D. Strayhorn,Wendell F. Rosse,George Phillips,D. Peace,A. Johnson-Telfair,Lisa Daitch,Paul F. Milner,A. Tracy,S. Valdez,G. E. Allen,J. Moshang,B. Scott,Carolyn Bigelow,A. Anderson,V. Sabahi,T. Harrington,W. Labrousse,Charles H. Pegelow,D. Temple,E. Case,R. Harrell,S. Childerie,Stephen H. Embury,B. Schmidt,D. Davies,Yogen Saunthararajah,Mabel Koshy,N. Talischy-Zahed,L. Dorn,G. Pendarvis,M. McGee,Margaret Telfer,A. Davis,O. C. Onyekwere,C. Nwokolo,Helga Finke,Elliott Perlin,J. Siteman,M. Bryan,T. Saunders,Y. Barber,P. Gascon,P. Di Paolo,S. Gargiulo,James R. Eckman,E. Carter-Randall,J. H. Bailey,A. Platt,L. Waller,G. Ramirez,V. Knors,S. Hernandez,E. M. Rodriguez,E. Wilkes,Elliott Vichinsky,Ward Hagar,C. Hoehner,E. Hackney-Stevens,S. Claster,A. Earles,K. Kleman,K. McLaughlin,L. White,B. Maddox,L. Usry,A. Brenner,K. Williams,R. O'Brien,K. Genther,Susan B. Shurin,Brian W. Berman,K. Chiarucci,L. Keverline,Nancy F. Olivieri,J. Chow,M. Hui,D. Shaw,N. Lewis,Maureen Okam,Elyse Mandell,A. Palmer,Kenneth Bridges,B. Tynan,C. Winograd,Rita Bellevue,Harvey Dosik,M. Sheikhai,P. Ryans,H. Souffrant,Brian Adler,L. Eskridge,Josef T. Prchal,J. Braddock,T. McArdle,Timothy M. Carlos,A. Roundtree-Schmotzer,D. Gardner +109 more
TL;DR: It is suggested that long‐term use of hydroxyurea is safe and might decrease mortality, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment.
Journal ArticleDOI
Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.
K Stam,Nora Heisterkamp,Gerard Grosveld,A de Klein,R. S. Verma,Morton Coleman,Harvey Dosik,John Groffen +7 more
TL;DR: All five patients with chronic myelocytic leukemia had chimeric bcr/c-abl messenger RNA, suggesting that the deleterious effects of this disease can be associated with an abnormal chimeric protein encoded by the bcr and the c-abl oncogene.